Valuation : Ligand Pharmaceuticals Incorporated

Market Cap 567.21Cr 488.76Cr 458.26Cr 418.33Cr 788.07Cr 54TCr 790.57Cr 5.44TCr 2.12TCr 27TCr 2.13TCr 2.08TCr 91TCr P/E 2026 *
54.3x
P/E 2027 * 33.3x
Enterprise Value 567.21Cr 488.76Cr 458.26Cr 418.33Cr 788.07Cr 54TCr 790.57Cr 5.44TCr 2.12TCr 27TCr 2.13TCr 2.08TCr 91TCr EV / Sales 2026 *
19.6x
EV / Sales 2027 * 14.9x
Free-Float
97.62%
Yield 2026 *
-
Yield 2027 * -
1 day-1.90%
1 week-2.86%
Current month-3.28%
1 month-6.14%
3 months+18.51%
6 months+37.30%
Current year+47.09%
1 week 277.01
Extreme 277.0074
289.66
1 month 277.01
Extreme 277.0074
317.49
Current year 175.89
Extreme 175.89
326.63
1 year 160.05
Extreme 160.05
326.63
3 years 49.24
Extreme 49.24
326.63
5 years 49.24
Extreme 49.24
326.63
10 years 49.24
Extreme 49.24
326.63
Manager TitleAgeSince
Chief Executive Officer 65 05/12/2022
Director of Finance/CFO 47 21/05/2015
Director of Finance/CFO 56 01/11/2022
Director TitleAgeSince
Chairman 76 01/03/2003
Director/Board Member 57 27/09/2006
Director/Board Member 65 01/03/2007
Date Insider Type Main position Quantity % Market Cap.
12/08/26 Fiscal year

Chief Financial Officer

94,923 0.4736%
12/08/26 Fiscal year

Director

19,414 0.0969%
03/08/26 Fiscal year

General Counsel

15,000 0.0748%
Change 5-day change 1-year change 3-year change Capi.($)
-1.90%-2.86%+73.86%+328.11% 567.21Cr
-0.42%-6.61%+60.17%+111.65% 1,04800Cr
+0.18%-1.51%+51.70%+62.00% 64TCr
-0.50%-2.84%+23.81%+74.61% 46TCr
-1.46%-4.50%+37.43%+38.41% 36TCr
-0.72%-2.89%+21.86%+36.79% 29TCr
-1.19%-2.21%+1.35%+10.79% 26TCr
-1.15%-1.47%+51.56%+68.72% 24TCr
+0.08%-1.78%-17.64%-54.29% 20TCr
-1.91%+0.04%+29.87%+89.75% 18TCr
Average -0.86%-0.75%+33.40%+76.65% 36.87TCr
Weighted average by Cap. -0.57%-1.92%+38.49%+65.61%

Financials

2026 *2027 *
Net sales 29Cr 25Cr 23Cr 21Cr 40Cr 2.77TCr 40Cr 277.81Cr 108.39Cr 1.4TCr 108.81Cr 106.45Cr 4.64TCr 38Cr 33Cr 31Cr 28Cr 53Cr 3.64TCr 53Cr 364.73Cr 142.3Cr 1.84TCr 142.86Cr 139.75Cr 6.09TCr
Net income 11Cr 9.64Cr 9.04Cr 8.25Cr 16Cr 1.07TCr 16Cr 107.21Cr 42Cr 539.61Cr 42Cr 41Cr 1.79TCr 19Cr 16Cr 15Cr 14Cr 26Cr 1.79TCr 26Cr 179.15Cr 70Cr 901.69Cr 70Cr 69Cr 2.99TCr
Net Debt - -
Logo Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company. It operates as a royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. It owns and manages portfolios of biopharmaceutical royalties, with economic interests in more than 200 development and commercial-stage assets. It funds high-value programs in exchange for long-term economic interests. It also licenses its proprietary technologies, Captisol and NITRICIL, to support drug development and formulation across its global partner network. Its commercial products include Roche's VABYSMO (faricimab-svoa), Servier's OJEMDA (tovorafenib), and Zevra Therapeutics' MIPLYFFA (arimoclomol). Additionally, it includes 14 late-stage development programs, featuring Takeda’s mezagitamab and certain assets from Takeda’s externalized asset portfolio, such as osavampator, volixibat, and OHB-607, along with more than 100 assets in various stages of development.
Employees
47
Date Price Change Volume
28/26/28 $278.10 -2.26% 43,873
27/26/27 $284.52 -1.16% 2,06,326
26/26/26 $287.85 +2.18% 1,47,463
25/26/25 $281.72 +0.55% 1,97,406
24/26/24 $280.18 -2.13% 1,58,235
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
284.52USD
Average target price
342.82USD
Spread / Average Target
+20.49%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LGND Stock